Muscle invasive bladder cancer (MIBC) is an aggressive form of bladder cancer that requires careful, individualized treatment. In this recording from our education event on April 15, 2024, in Toronto, ON, Dr. Alexandre Zlotta speaks about the management of muscle invasive bladder cancer and sheds light on current and forthcoming treatment options. He delves into the option of bladder preservation or Trimodal Therapy (TMT), including studies, patient outcomes, and the criteria used to select patients for this innovative treatment option.
Understanding Muscle Invasive Bladder Cancer
Muscle invasive bladder cancer affects the muscle layer of the bladder wall and represents roughly 25–30% of newly diagnosed bladder cancers. Unlike non-muscle invasive bladder cancer, MIBC is potentially life-threatening and often requires multimodal treatment. Early diagnosis and tailored management strategies are critical to improving patient survival and maintaining quality of life.
Radical Cystectomy: The Traditional Standard for MIBC Treatment
For decades, radical cystectomy (the removal of the bladder) has been considered the gold standard for treating MIBC. While highly effective at controlling disease, this surgery does impact urinary and sexual function. Dr. Alexandre Zlotta emphasizes that radical cystectomy is a key treatment option but may not be necessary for every patient, opening the door to alternative strategies.
Bladder Preservation and Trimodal Therapy (TMT) for MIBC
A major advancement in MIBC care is bladder preservation, often achieved through trimodal therapy (TMT). TMT combines:
- Maximal tumor resection
- Chemotherapy to enhance the effectiveness of radiation
- Targeted radiation therapy
This approach is suitable for patients with a single, localized tumor, good bladder function, and limited disease spread. Clinical studies demonstrate that TMT can achieve outcomes comparable to radical cystectomy, highlighting the value of personalized, multidisciplinary care.
Emerging Treatments and Personalized Strategies for MIBC Patients
Ongoing bladder cancer research is expanding options for MIBC patients. Innovations include:
- New systemic chemotherapy combinations
- Immunotherapy and checkpoint inhibitors
- Antibody-drug conjugates (ADCs) targeting tumor-specific markers
- Genetic profiling and circulating tumor DNA to guide treatment decisions
These advances aim to increase eligibility for bladder preservation while improving overall outcomes, offering hope for patients seeking alternatives to radical surgery.
Partner with Bladder Cancer Canada for Support and Resources
The management of MIBC is complex, and staying informed is essential. Bladder Cancer Canada provides patients and caregivers with educational resources, webinars, and support programs to navigate treatment decisions. From understanding radical cystectomy to exploring bladder preservation and emerging therapies, the organization helps patients make informed choices for their care.
